← Back to headlines
AbbVie Reports Positive Late-Stage Results for Subcutaneous Skyrizi in Crohn's Disease
AbbVie announced positive late-stage clinical trial results for its subcutaneous Skyrizi treatment in patients with Crohn's disease, indicating potential for a new therapeutic option.
2 Mar, 16:31 — 2 Mar, 16:31
ℹOnly 1 source covers this story
